Tuberculosis therapy and enzyme induction in man.
The enzymatic inducing effect of an antituberculous treatment (Rifampicin, Isoniazid and Ethambutol) is tested by recording variations in the urinary D-glucaric acid elimination and in the antipyrine half-life test, measured before starting treatment and after two weeks of treatment. This study concerns 21 patients: 14 are slow acetylators and 7 are rapid acetylators of isoniazid. After two weeks of treatment an increase of the urinary glucaric acid elimination is observed but variations in the antipyrine half-life test are not univocal and allow us to separate two categories of patients: 10 have a significant decrease of antipyrine half-life, 11 have not. A link seems to exist between the rapid acetylator phenotype and this enzyme induction which is revealed by the antipyrine test. An interpretation of these two enzyme induction tests, the nature of the rifampicin inducing action and its relation to the acetylator phenotype are discussed.
D000107:Acetylation; D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000494:pharmacology; D000995:Antitubercular Agents / Q000494:pharmacology*; D004790:Enzyme Induction / Q000187:drug effects*; D004977:Ethambutol / Q000494:pharmacology; D005260:Female; D006207:Half-Life; D006801:Humans; D007538:Isoniazid / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D012293:Rifampin / Q000494:pharmacology; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy / Q000201:enzymology*
D000995:Antitubercular Agents; D004977:Ethambutol; D000983:Antipyrine; D007538:Isoniazid; D012293:Rifampin